High Dose of Erythropoietin Analogue After Cardiac Arrest (Epo-ACR-02)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00999583|
Recruitment Status : Completed
First Posted : October 22, 2009
Last Update Posted : June 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Comatose Survivors of Cardiac Arrest||Drug: EPOETINE ALPHA Other: Control arm||Phase 3|
A recent pilot study showed encouraging results regarding the potentially beneficial effects of high dose epoetin alpha (an analogue of erythropoietin) when administered early after cardiac arrest. In this open label and non randomized trial, a high proportion of patients survived without significant cerebral disability and without experiencing severe adverse events (CARIOU et al. Resuscitation 2008). Efficiency of this treatment should now be evaluated in a randomized trial.
An early administration of a high dose of epoetin alpha (Epo) after cardiac arrest resuscitation could improve the neurological outcome of these patients by comparison with standard treatment. The proportion of patients reaching the level 1 of the Pittsburgh CPC scale (i.e., no or minor cerebral disability) at day 60 could attain 45% in the interventional group versus 30% as expected in the control group.
Multicentre, randomised, controlled, simple blind trial ("add on study").
To test the efficiency of a high dose of Epo administered at the early stage of the post-cardiac arrest period regarding its ability to improve the neurological outcome of these patients, when compared with standard care (including hypothermia when indicated).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||High Dose of Erythropoietin Analogue After Cardiac Arrest: a Multicentre, Randomised, Controlled Trial (Epo-ACR-02 Trial)|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||May 2014|
five injections maximum of 40000 UI EPO
Drug: EPOETINE ALPHA
5 injections of 40000 UI of EPO
Active Comparator: Control
Classical take care
Other: Control arm
Usual take care of cardiac arrest
- Number of patients reaching a CPC (cerebral performance category) level 1 in each group [ Time Frame: at day 60 ]
- Distribution of patients in CPC (cerebral performance category) scale [ Time Frame: at day 30 and day 60 ]
- ICU, hospital D30 and D60 mortality [ Time Frame: during hospitalization and at day 30 and day 60 ]
- All adverse events (including thrombotic events) [ Time Frame: until day 60 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00999583
|Medical intensive care unit of Cochin-St Vincent de Paul university Hospital|
|Paris, France, 75679|
|Principal Investigator:||Alain Cariou, MD, PhD||Assistance Publique - Hôpitaux de Paris|